Diaceutics Plc · LSE:DXRX
Diaceutics — Diaceutics Clinical Practice Gaps: Webinar Series (July 2024)
8 slides from Diaceutics's conference presentation, July 2024
Slide 1: Diaceutics Clinical Practice Gaps: Webinar Series Q&A
Diaceutics Clinical Practice Gaps: Webinar Series Understanding the challenges the precision medicine industry faces in ensuring every patient receives the right therapy for them, a NSCLC case study Q&A Peter Keeling Susanne Munksted Daryl Pritchard Chief Executive Chief Precision Senior Vice Presid
Slide 2: Question 1 and Question 2
Question 1 Question 2 How reflective of real life is this Have you any perspective on key shifts in this since 2019? Do study? you think the situation has improved or got worse? Any thought on how current the perspective we’re sharing today is? Susanne: This is a fairly reflective study of real-life
Slide 3: Question 3 and Question 4
Question 3 Question 4 What impact could this have on Has the information presented here today been presented to the advancement of precision payers, insurance companies, etc. to help expand coverage medicine and how do you think it for additional testing that had not been previously covered by will
Slide 4: Question 5
Question 5 Susanne, could you discuss the lab community. What role do you think the labs have to play here and what do we need to do to help them? Susanne: That’s a really important aspect of this, because I do think that this paper will be that call to action, that is generates the spotlight to lab
Slide 5: Question 6
Question 6 If you could tackle one gap, which one would you tackle first? Daryl: I’ll make the argument that we should focus on the early the ones upstream that the clinical practice gaps around biospecimen collection, test performance and clinical decision support, because I think there’s already s
Slide 6: Question 7
Question 7 Having delivered the practice gaps study, what do you think would be the number one takeaway for pharma? Susanne: Having had the opportunity to talk about the data and present the data at several meetings and having had discussions with several stakeholders including pharma it does come a
Slide 7: Question 8 and Question 9
Question 8 Question 9 Did this project look at different barriers at different I think that level of complexity will increase stages of NSCLC? For example, prior to first line and in fact it was one of the questions is treatment or second line treatment and how relevant this not going to get more co
Slide 8: Question 10
Question 10 What is the role of liquid biopsy and how does this help? Is it helping universally? Download the paper for more Daryl: Yes, it does help universally and there are challenges to collecting liquid information on the Practice Gaps biopsy samples as well. And then all those post collection
Diaceutics — Diaceutics Clinical Practice Gaps: Webinar Series (July 2024) on 6ix